Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies

A C Poon, G Geerling, J K Dart, G E Fraenkel, J T Daniels, A C Poon, G Geerling, J K Dart, G E Fraenkel, J T Daniels

Abstract

Background/aims: Autologous serum drops have been reported to be beneficial in keratoconjunctivitis sicca (KCS) and persistent epithelial defects (PED). A clinical pilot study was carried out to examine these potential uses and in vitro toxicity testing on corneal epithelial cell cultures was performed to compare the effect of serum drops with unpreserved hypromellose (hydroxypropylmethylcellulose 0.3%).

Methods: Patients with KCS and PED, unresponsive to conventional treatment were recruited. Patients were examined before treatment, at 1 and 2 weeks after initiation, and then 2 weekly until treatment ceased. Symptoms were assessed at each visit. Clinical examination included Schirmer's test without anaesthesia, rose bengal staining, and fluorescein staining. Epithelial defects were measured with the slit beam. In the laboratory, cultured human corneal epithelial cells were exposed to serum drops and hypromellose, and their viability evaluated with fluorescent viability staining (Calcein AM ethidium homodimer) and an ATP assay.

Results: Autologous serum was used in 15 eyes of 13 patients with PED and 11 eyes of nine patients with KCS. In two patients serum drops were started after penetrating keratoplasty (PK). The PKs were performed for perforations secondary to PEDs. Of the 15 eyes with PED, nine healed at a mean of 29 days and six failed. The mean duration of PED before the use of serum drops was 48.2 days. Of the 11 eyes with KCS, six had improved subjective scores and fluorescein scores, and five had improved rose bengal scores after the use of serum drops. For the two patients who used serum eyedrops post-PK, there was a stable and intact epithelium at 1 week. Cessation of serum drops during the postoperative period led to deterioration in the subjective and objective scores in both patients. One developed a PED that responded to reinstitution of serum drops. The morphology and ATP levels of cultured epithelial cells exposed to serum were better maintained than those exposed to hypromellose.

Conclusion: Autologous serum drops are useful for PED and KCS. This effect may be related to a number of active factors in serum including growth factors, fibronectin, vitamin A, and anti-proteases. In vitro toxicity testing demonstrated that serum drops have reduced toxicity compared with unpreserved hypromellose. Currently regulatory restrictions in the UK have prevented the establishment of a prospective randomised controlled trial examining the efficacy of autologous serum drops for the management of this group of ocular surface disorders.

Figures

Figure 1
Figure 1
This is a 74 year old man with KCS secondary to rheumatoid arthritis. History includes left infective corneal melt 3 years ago requiring a tectonic PK. This was followed by recurrent epithelial breakdown unresponsive to intensive lubrication and SRCL wear. The cornea perforated again requiring a repeat PK 3 months before the start of serum drops. The PED recurred and amniotic membrane transplantation was tried but failed to heal it. Serum drops were started subsequently. (A, B) Show a PED with and without fluorescein and cobalt blue illumination before the start of serum. (C) Shows that healing occurred in 2 months (epithelial bullae at site of PED). Serum was stopped after 2 months, and the PED recurred (D). It failed to respond to any therapy apart from the reinstitution of serum. (E) and (F) show healed defect with and without cobalt blue illumination. The PED recurred with further attempts at weaning and healed with reinstitution of serum. At the last review serum was weaned for the fourth time.
Figure 2
Figure 2
A 52 year old female with OCP, bilateral KCS, and left PK. Bilateral epitheliopathy was secondary to KCS. (A) and (B) show right and left eyes respectively. Serum drops were started and (C) and (D) were taken at 2 week review. Despite the absence of fluorescein in (C) and (D), there are obviously fewer surface irregularities and episcleral injection in the second set of photographs. Both objective and subjective scores had improved.
Figure 3
Figure 3
Human corneal epithelial cells after 2 hours' incubation with (A) hypromellose 0.3% and (B) 50% serum drops. The green fluorescent calcein demonstrates viable intracellular esterase activity. The red fluorescence results from ethidium-homodimer bound to nucleic acids as a consequence of a pathological increase in cell membrane permeability.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1723716/bin/bjo-csoonm.f1.jpg

References

    1. Ophthalmologica. 1993;206(3):119-24
    1. Ophthalmology. 1999 Oct;106(10):1984-9
    1. Bioessays. 1994 Feb;16(2):133-8
    1. Adv Exp Med Biol. 1994;350:441-52
    1. Adv Exp Med Biol. 1994;350:453-7
    1. Am J Ophthalmol. 1995 Mar;119(3):281-7
    1. Eye (Lond). 1995;9 ( Pt 1):110-5
    1. Fundam Appl Toxicol. 1995 May;25(2):253-63
    1. Exp Dermatol. 1995 Aug;4(4 Pt 1):183-91
    1. Hum Immunol. 1993 Aug;37(4):264-70
    1. Int Ophthalmol Clin. 1975 Winter;15(4):49-66
    1. Am J Ophthalmol. 1983 Mar;95(3):353-8
    1. CLAO J. 1995 Oct;21(4):221-32
    1. Am J Ophthalmol. 1996 Jul;122(1):38-52
    1. J Cell Physiol. 1996 Oct;169(1):159-66
    1. J Cell Sci. 1997 Jan;110 ( Pt 2):113-21
    1. Isr J Med Sci. 1997 Mar;33(3):194-7
    1. Am J Ophthalmol. 1997 Dec;124(6):825-35
    1. Arch Ophthalmol. 1983 Jul;101(7):1046-8
    1. Trans Ophthalmol Soc U K. 1985;104 ( Pt 4):402-9
    1. Arthritis Rheum. 1986 May;29(5):577-85
    1. Am J Ophthalmol. 1987 Jun 15;103(6):802-7
    1. Am J Ophthalmol. 1987 Nov 15;104(5):494-501
    1. Curr Eye Res. 1987 Oct;6(10):1205-9
    1. Aust N Z J Ophthalmol. 1987 Nov;15(4):257-62
    1. Cornea. 1988;7(2):96-101
    1. Arch Ophthalmol. 1988 Oct;106(10):1423-5
    1. Ophthalmologica. 1988;197(4):179-84
    1. Vet Clin North Am Small Anim Pract. 1990 May;20(3):627-42
    1. Ophthalmology. 1992 Jun;99(6):873-8
    1. Cornea. 1992 Jul;11(4):311-4
    1. Curr Eye Res. 1993 Aug;12(8):733-40
    1. Br J Ophthalmol. 1999 Apr;83(4):390-5

Source: PubMed

3
Abonnere